Korro Bio, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Korro Bio, Inc. (KRRO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Korro Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.70M, a 35.29% increase year-over-year.
- Korro Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.73M, a 55.08% increase year-over-year.
- Korro Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.82M, a 43.36% increase year-over-year.
- Korro Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.00M, a 106.62% increase year-over-year.
- Korro Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $7.66M, a 71.56% increase from fiscal 2024.
- Korro Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $4.46M, a 87.87% increase from fiscal 2023.
- Korro Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.38M, a 110.36% increase from fiscal 2022.
- Korro Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.13M, a 94.81% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.70M 10-Q · filed 2026-08-06 | $5.43M derived: sum of 2 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $2.73M 10-Q · filed 2026-08-06 | |||||
| 2025-12-31 | $7.66M 10-K · filed 2026-03-12 | |||||
| 2025-09-30 | $1.82M 10-Q · filed 2025-11-12 | $3.82M derived: sum of 2 quarters · filed 2026-08-06 | $5.58M derived: sum of 3 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $2.00M 10-Q · filed 2026-08-06 | $3.76M derived: sum of 2 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $1.76M 10-Q · filed 2026-08-06 | |||||
| 2024-12-31 | $4.46M 10-K · filed 2026-03-12 | |||||
| 2024-09-30 | $1.27M 10-Q · filed 2025-11-12 | $2.24M derived: sum of 2 quarters · filed 2025-11-12 | $3.10M derived: sum of 3 quarters · filed 2025-11-12 | -$3.77M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $967.00K 10-Q · filed 2025-11-12 | $1.83M derived: sum of 2 quarters · filed 2025-11-12 | -$5.05M derived: sum of 3 quarters · filed 2025-11-12 | -$4.64M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $865.00K 10-Q · filed 2025-11-12 | -$6.01M derived: sum of 2 quarters · filed 2025-11-12 | -$5.61M derived: sum of 3 quarters · filed 2025-11-12 | -$5.21M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2023-12-31 | -$6.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$6.47M derived: sum of 2 quarters · filed 2025-03-18 | -$6.07M derived: sum of 3 quarters · filed 2025-03-18 | $2.38M 10-K · filed 2025-03-18 | ||
| 2023-09-30 | $404.00K 10-Q · filed 2024-11-12 | $2.92M 10-Q · filed 2023-11-02 | $805.00K derived: sum of 2 quarters · filed 2024-11-12 | $9.25M 10-Q · filed 2023-11-02 | -$13.15M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $401.00K 10-Q · filed 2024-11-12 | $2.90M 10-Q · filed 2023-08-10 | $6.33M 10-Q · filed 2023-08-10 | -$13.55M derived: sum of 3 quarters · filed 2024-11-12 | -$7.96M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-03-31 | $343.00K 10-Q · filed 2024-11-12 | $3.43M 10-Q · filed 2023-05-12 | -$13.95M derived: sum of 2 quarters · filed 2024-11-12 | -$8.36M derived: sum of 3 quarters · filed 2024-11-12 | -$3.79M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2022-12-31 | -$14.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$8.70M derived: sum of 2 quarters · filed 2024-03-26 | -$4.14M derived: sum of 3 quarters · filed 2024-03-26 | $1.13M 10-K · filed 2024-03-26 | $19.83M 10-K · filed 2023-03-10 | |
| 2022-09-30 | $5.59M 10-Q · filed 2023-11-02 | $10.16M derived: sum of 2 quarters · filed 2023-11-02 | $15.43M 10-Q · filed 2023-11-02 | $20.59M derived: sum of 4 quarters · filed 2023-11-02 | ||
| 2022-06-30 | $4.56M 10-Q · filed 2023-08-10 | $9.83M 10-Q · filed 2023-08-10 | $14.99M derived: sum of 3 quarters · filed 2023-08-10 | $20.88M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $5.27M 10-Q · filed 2023-05-12 | $10.43M derived: sum of 2 quarters · filed 2023-05-12 | $16.32M derived: sum of 3 quarters · filed 2023-05-12 | $22.41M derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $11.05M derived: sum of 2 quarters · filed 2023-03-10 | $17.14M derived: sum of 3 quarters · filed 2023-03-10 | $21.75M 10-K · filed 2023-03-10 | ||
| 2021-09-30 | $5.89M 10-Q · filed 2022-11-08 | $11.97M derived: sum of 2 quarters · filed 2022-11-08 | $16.59M 10-Q · filed 2022-11-08 | $19.35M derived: sum of 4 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $6.09M 10-Q · filed 2022-08-09 | $10.70M 10-Q · filed 2022-08-09 | $13.46M derived: sum of 3 quarters · filed 2022-08-09 | $16.11M derived: sum of 4 quarters · filed 2022-08-09 | ||
| 2021-03-31 | $4.61M 10-Q · filed 2022-05-04 | $7.38M derived: sum of 2 quarters · filed 2022-05-04 | $10.02M derived: sum of 3 quarters · filed 2022-05-04 | $12.43M derived: sum of 4 quarters · filed 2022-05-04 | ||
| 2020-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $5.41M derived: sum of 2 quarters · filed 2022-03-15 | $7.82M derived: sum of 3 quarters · filed 2022-03-15 | $9.98M 10-K · filed 2022-03-15 | ||
| 2020-09-30 | $2.64M 10-Q · filed 2021-11-15 | $5.05M derived: sum of 2 quarters · filed 2021-11-15 | $7.22M 10-Q · filed 2021-11-15 | $8.37M derived: sum of 4 quarters · filed 2021-11-15 | ||
| 2020-06-30 | $2.41M 10-Q · filed 2021-08-12 | $4.58M 10-Q · filed 2021-08-12 | $5.73M derived: sum of 3 quarters · filed 2021-08-12 | $6.65M derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $2.16M 10-Q · filed 2021-05-13 | $3.32M derived: sum of 2 quarters · filed 2021-05-13 | $4.24M derived: sum of 3 quarters · filed 2021-05-13 | $5.72M derived: sum of 4 quarters · filed 2021-05-13 | ||
| 2019-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $2.08M derived: sum of 2 quarters · filed 2021-03-29 | $3.56M derived: sum of 3 quarters · filed 2021-03-29 | $3.61M 10-K · filed 2021-03-29 | ||
| 2019-09-30 | $925.00K 10-Q · filed 2020-11-16 | $2.41M derived: sum of 2 quarters · filed 2020-11-16 | $2.46M 10-Q · filed 2020-11-16 | $2.64M derived: sum of 4 quarters · filed 2020-11-16 | ||
| 2019-06-30 | $1.48M 10-Q · filed 2020-08-12 | $1.53M 10-Q · filed 2020-08-12 | $1.72M derived: sum of 3 quarters · filed 2020-08-12 | $1.82M derived: sum of 4 quarters · filed 2020-08-12 | ||
| 2019-03-31 | $49.00K 10-Q · filed 2020-05-14 | $237.00K derived: sum of 2 quarters · filed 2020-05-14 | $339.00K derived: sum of 3 quarters · filed 2020-05-14 | |||
| 2018-12-31 | $188.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $290.00K derived: sum of 2 quarters · filed 2020-03-26 | $455.00K 10-K · filed 2020-03-26 | |||
| 2018-09-30 | $102.00K 10-Q · filed 2019-11-18 | $267.00K 10-Q · filed 2019-11-18 | ||||
| 2017-12-31 | $91.00K 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |